Aclidinium

• COPD (Chronic Obstructive Pulmonary Disease)
• Chronic Bronchitis
• Emphysema

Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) used as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD). This inhaled medication provides sustained bronchodilation to improve breathing and reduce COPD symptoms.

Mechanism of Action

Aclidinium is an anticholinergic medication that works by blocking muscarinic M3 receptors in the smooth muscle of the airways. In COPD, excessive parasympathetic (cholinergic) activity leads to bronchoconstriction, mucus hypersecretion, and airway inflammation. By competitively inhibiting acetylcholine binding to M3 receptors, aclidinium causes relaxation of bronchial smooth muscle, resulting in bronchodilation. The medication has high selectivity for M3 receptors and is rapidly hydrolyzed in plasma, which contributes to its favorable safety profile with minimal systemic anticholinergic effects. The bronchodilatory effect begins within 30 minutes and lasts approximately 12 hours, supporting twice-daily dosing.

Available Formulations

Aclidinium is available as a dry powder inhaler (Pressair/Genuair device) delivering 400 mcg per actuation. The device provides visual (green window) and audible (click) feedback to confirm successful dose delivery. It is also available in fixed-dose combinations with formoterol (a long-acting beta-agonist) for patients requiring dual bronchodilation.

Medical Uses

Aclidinium is indicated for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is not indicated for the relief of acute bronchospasm or for the treatment of asthma. Clinical trials demonstrated significant improvements in lung function (measured by FEV1), COPD symptoms, and health-related quality of life compared to placebo. The medication is particularly useful for patients with nighttime or early morning symptoms due to its twice-daily dosing.

Dosing Guidelines

The recommended dose is one inhalation (400 mcg) twice daily, approximately 12 hours apart, morning and evening. No dose adjustment is necessary based on age, hepatic impairment, or mild to moderate renal impairment. Patients should be instructed on proper inhaler technique, including holding the device horizontally, pressing and releasing the green button, exhaling away from the device, and then inhaling forcefully through the mouthpiece. The colored control window should change from red to green when the dose is ready and back to red after inhalation.

Important Safety Information

Aclidinium should not be used for acute bronchospasm or as rescue therapy. Like other anticholinergic medications, it should be used with caution in patients with narrow-angle glaucoma, urinary retention, or prostatic hyperplasia. Paradoxical bronchospasm may occur with inhaled bronchodilators; if this occurs, aclidinium should be discontinued immediately. Immediate hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported. Patients with severe hypersensitivity to milk proteins should not use this medication.

Drug Interactions

Aclidinium should not be used concurrently with other anticholinergic-containing medications, as this may increase the risk of anticholinergic side effects. There are no significant interactions with other commonly used COPD medications, including inhaled corticosteroids, beta-agonists, and theophylline. Due to rapid plasma hydrolysis, aclidinium has minimal systemic exposure, reducing the potential for drug-drug interactions mediated through hepatic metabolism.

Special Populations

There are no adequate studies of aclidinium in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether aclidinium is excreted in human breast milk; caution should be exercised when administering to nursing women. Safety and efficacy have not been established in pediatric patients. No dose adjustment is needed for elderly patients. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) were not studied in clinical trials. No dose adjustment is needed for patients with hepatic impairment, though those with severe impairment were not studied.